US Patent Issued to Genentech, Hoffmann-La Roche on March 18 for "Pertuzumab plus trastuzumab fixed dose combination" (Swiss, British, American Inventors)

ALEXANDRIA, Va., March 19 -- United States Patent no. 12,252,549, issued on March 18, was assigned to Genentech Inc. (South San Francisco, Calif.) and Hoffmann-La Roche Inc. (Little Falls, N.J.).

"Pertuzumab plus trastuzumab fixed dose combination" was invented by Tanja Badovinac-Crnjevic (Basel, Switzerland), Yu Chien Fredriksson (Basel, Switzerland), Sarah Heeson (Welwyn Garden, Great Britain), Ihsan Hamdi Nijem (Brisbane, Calif.), Whitney Paige Kirschbrown (San Mateo, Calif.) and Eleonora Restuccia (Basel, Switzerland).

According to the abstract* released by the U.S. Patent & Trademark Office: "The invention disclosed concerns a fixed dose combination (FDC) of pertuzumab, trastuzumab, and, optionally, recombinant human hyaluronidase (r...